Scienture revenue rose 216%, REZENOPY due Q2

Cash stood at $6.7M with $5.2M in working capital at year-end, giving an estimated 12-month runway as Arbli expands and REZENOPY nears Q2 launch.

Apr. 6, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

Scienture, a holding company for pharmaceutical operating companies, reported a 216% increase in revenue in 2025 driven by the commercial launch of its first internally developed product, Arbli. The company also announced plans to launch REZENOPY, a high-dose naloxone nasal spray, in the second quarter of 2026. Scienture maintained a disciplined approach to capital management, fully repaying debt and ending the year with $6.7 million in cash and $5.2 million in working capital, providing a 12-month runway to support ongoing operations and growth initiatives.

Why it matters

Scienture's strong financial performance and pipeline progress demonstrate its ability to successfully commercialize branded pharmaceutical products and advance its strategy to build a differentiated specialty pharmaceutical platform. The upcoming launch of REZENOPY is expected to further strengthen the company's revenue base and market position in the growing opioid overdose treatment market.

The details

In 2025, Scienture achieved several key milestones, including the commercial launch of Arbli, its first internally developed product, and the strategic acquisition of REZENOPY. Arbli, a novel liquid formulation of losartan for hypertension, has been successfully introduced to the market, positioning the company to drive revenue growth. Looking ahead, Scienture expects to launch REZENOPY, the highest-dose FDA-approved naloxone nasal spray for emergency opioid overdose treatment, in the second quarter of 2026. The company has built a scalable commercial infrastructure and secured key distribution agreements to support the launch of REZENOPY and drive adoption in the $141 million U.S. naloxone market.

  • In March 2025, Scienture completed the strategic acquisition of REZENOPY.
  • In March 2025, Scienture received FDA approval for Arbli, its first internally developed product.
  • In September 2025, Scienture successfully commercially launched Arbli.
  • Scienture expects to launch REZENOPY in the second quarter of 2026.

The players

Scienture Holdings, Inc.

A holding company for pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products.

Arbli

Scienture's first internally developed product, a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension.

REZENOPY

Scienture's high-dose naloxone nasal spray for the emergency treatment of known or suspected opioid overdose.

Narasimhan Mani

Co-Chief Executive Officer of Scienture Holdings, Inc.

Shankar Hariharan

Co-Chief Executive Officer of Scienture Holdings, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“This past year marked a pivotal period for Scienture, as we advanced our strategy to build a differentiated, branded specialty pharmaceutical platform. We are pleased to share this annual update and highlight the progress we have made in executing our mission to deliver innovative therapies that improve patient outcomes while creating long-term shareholder value.”

— Narasimhan Mani, Co-Chief Executive Officer

“Over the next 12 months, we will focus on maximizing commercial performance by expanding market penetration of our existing products and broadening our portfolio, advancing our pipeline efficiently to achieve key clinical and regulatory milestones and bring new therapies to market, and scaling our infrastructure to support sustainable, long-term growth.”

— Shankar Hariharan, Co-Chief Executive Officer

What’s next

The judge in the Nasdaq compliance case will decide on April 13, 2026 whether to allow Scienture an additional 180-day period to regain compliance with the minimum bid price requirement.

The takeaway

Scienture's strong financial and operational performance, combined with its focused strategy and pipeline progress, position the company well to drive continued innovation, improve patient outcomes, and deliver long-term shareholder value as it expands its branded specialty pharmaceutical platform.